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Paraplegia and spinal cord injuries are issues of major concern to the actual medicine. But
recent advances have raised hopes for a better prognosis, which has always been poor or
infaust since medicine was practiced. However and interestingly enough, some concepts
and deﬁnitions on the occurrence have survived for millennia. Once encountered as an
issue, traumatic or non-traumatic paraplegia needs a multidisciplinary approach and a
careful staging of the problem. Different scales are available with Frankel's and American
Spinal Injury Association most widely used as alternatives or complementary tools. The
authors discuss therapeutic options with a special focus on the stem cell therapy which
has seen an impressive increase on the number of trials for a successful treatment.
Sourcing and yielding of stem cells are made possible through a number of techniques,
with material aspirated from bone marrow or adipose tissue, which are used along with
other sources of neuronal precursors such as olfactory ensheathing cells. Nevertheless,
large and multicenter studies are still lacking. However, with the quality of the ongoing
work and research, the optimistic attitude seems warranted. Meanwhile, other rehabili-
tation and medical care interventions, always at hand, need to be applied in every indi-
vidual suffering from paraplegia and spinal cord injury.1. Introduction
The traumatic, and even more the non-traumatic paraplegia,
always remaining a diagnostic and clinical challenge, has been a
part of medical discussions and publications ever since quota-
tions become an unavoidable element of the academic writings.
In his proliﬁc and pioneering work, Graves dedicated an entire
lecture to the issue of paralysis, though he explicitly chose the
term ‘paraplegia’ as its running head[1]. At that remote time of
the 19th century, ﬁnding out that nervous injuries could follow
a centripetal trajectory was highly sensitive, as Graves wrote:
“When a certain portion of the extreme branches of the
nervous tree has suffered an injury, the lesion is not conﬁned
merely to the part injured, but in many instances is propagated
back towards the nervous centers”[1]. After marshaling severalarguments that mirrored the general medical opinion of that
time, paraplegia occurred due to bowel inﬂammation or
enteritis. Nevertheless, Graves accepted that arsenical or lead
poisoning might quite well be an etiological factor, with both
the irritants acting directly on the central nervous system[1].
The paralysis of the lower extremities was more descriptive
and detailed in the second volume of Leroy d' E´tiolles work
published in 1857, which was widely deemed as a reference
source from his contemporaries[2]. After dedicating an entire
chapter to empoisonings leading to paraplegia (with a
particular emphasis on arsenical paralysis), and without
avoiding the notion of ‘intestinal irritation’ with a copious list
of causative infections in the sixth chapter of his work, the
French physician spoke about an idiopathic paraplegia in the
ensuing chapter of his work.
A single search on the PubMed with the term ‘paraplegia’
will produce more than 19700 quotations, with the most distant
one dating in 1827[3]. Earle took care of initial deﬁnition of the
term in his collection of cases, and for that precise reason, he
summoned several previous designations: “Hippocrates
denominates all paralytic affections occurring after apoplexy,BY-NC-
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sensation or motion in some one particular part. Boerhaave
says that paraplegia is a palsy of all parts below the neck”[3].
The long list of the alleged etiological factors of non-
traumatic paraplegia of an unknown origin was confusing to
historical authors of the medicine of 19th century. Brown-
Se´quard numbered more than twelve conditions leading to this
event in a part of one of his lectures. He wrote about ‘cases of
paraplegia’ due to diseases of the uterus, the urethra, the bladder
and prostate, nephritis and enteritis, as well as due to affections
of lungs or pleura, diphtheria, diseases of the knee joints, irri-
tation of the nerves of the skin and neuralgia, and even due to
teething. It seems that the famous physician had his own doubts
on the veracity of the factors included in the list. Therefore, he
intuitively recollected all of those under the term of ‘reﬂex
paraplegia’. His work, originally published as a lecture in The
Lancet in 1860, was thereafter printed in its complete form
Williams and Norgate[4].
After such a disparate historical spectrum of alleged factors
leading to non-traumatic paraplegia, it is obvious that the pro-
posed medical treatments of the period actually are of a pure
curiosity and largely obsolete. Graves mentioned several expe-
riences of his own treatment through purgatives, cupping to the
nape of the neck, diluents and opiates, moxae (a plant-parasitic
nematode) applied along the course of the spinal column, blisters
and liniments over the calf and the trajectory of the sciatica. But
he concluded that ‘strychnine’ and ‘sulphur’ are the only internal
remedies of beneﬁt[1].
2. Classiﬁcatory attempts
Clear as it is, the term paraplegia is equivalent to a complete
paralysis of the legs and the lower body. Incomplete lesions are
given the denotation of paraparesis. Hippocrates was the ﬁrst
one to introduce the term, and his deﬁnition was given at the
introductory notes. The famous physician thought that the
occurrence was related with a blow of the disease, whence
‘stroke’[5]. The word itself is composed from para (para –
beside, from the Greek) and plessein (plhgή – to strike, from
the Greek).
The word itself has an ominous hint. In fact, the morbidity
and disability produced from complete spinal cord lesions are
exceptionally high. However, in view of continuous medical
research and progress, infaust prognosis might not always be
inescapable. The change of the prestigious journal titled ‘Para-
plegia’ (published in 1963–1996) into ‘Spinal cord’ (since 1996
one of the journals of Springer Nature) reﬂects fairly well the
optimistic attitude that is characterized over the last two decades.
In order to assess the severity of the neurological impairment,
several scales have been proposed. Frankel scale, proposed in
1969, was a simple measure of 5-points (Table 1).Table 1
The Frankel scale for spinal cord injury (SCI)[6].
Frankel scale Cha
A Complete No
B Sensory only No
C Motor useless Som
D Motor useful Use
E Recovery NorThe American Spinal Injury Association (ASIA) and the
International Spinal Cord Society have proposed another scale,
modifying the Frankel's, and this is actually the most widely
used clinical tool to quantify the severity of SCI[7]. The revised
scale, known as the ‘ASIA Impairment Scale’, is reproduced
in Table 2. Meanwhile, the international standards for the
neurological classiﬁcation of the SCI are reviewed and revised
several times[8,9].
Other authors have suggested that relying on the sacral
sparing as a criterion for complete spinal injury is more reliable
than the criteria used by ASIA, which depends on the neuro-
logical level of injury and the width of the zone of partial
preservation[10]. Obviously, sacral sparing of some functionality
is of particular signiﬁcance in view of preservation of some
involuntary sphincter contractility. However, these slight
classiﬁcatory changes in between sources are not conceptual,
and the impairment scales correspond largely to one another.
Most importantly, grading the severity of the spinal cord
trauma has a clear prognostic value, since a complete injury
after the initial acute phase has a poor outcome; it seems that
the ﬁrst 24 h is not only decisive, but sufﬁcient to draw
conclusions about the completeness or not of the irreversibility
of the spinal injury[11].
3. Treatment: from bench to bedside
Large-scale studies have been so far mainly focused on the
timeliness and dosage of methylprednisolone, whose efﬁcacy
during the acute phase of SCI is widely accepted. Three studies
named National Acute Spinal Cord Injury I, II and III have
already published their promising results[12–14]. High-dose dexa-
methasone is another glucocorticoid agent applied with some
efﬁcacy[15]. Among the disparate pharmacological options
suggested and applied by different authors with some extent of
efﬁcacy, other potent glucocorticoids have been suggested
(such as tirilazad mesylate), even through combining steroid
therapy with local hypothermia. But GM1 ganglioside,
naloxone, 4-aminopyridine, guanosine derivatives and agents
with stem/progenitor cell proliferative properties (such as cur-
cumin) have been tried as well[12–19]. Electrostimulation
(alternating current stimulation) and elective neurosurgery
(decompressive laminectomy) should be taken into
consideration accordingly. Nevertheless, the actual focus of
study has been shifted toward transplantation modalities,
namely, the stem cell therapy.
Albeit not unknown to the scientiﬁc circles, stem cell therapy
for SCI is a relatively new method. However, its successful
application in a diversity of studies, some of which have already
achieved their second phase, has raised consistent hopes[17–19].
The ﬁrst issue of concern is where to ﬁnd and produce enough
precursors of the neurons, largely damaged during the SCI.racteristics
motor or sensory function below level of lesion
motor function, but some sensation is preserved below level of lesion
e motor function without practical application
ful motor function below level of lesion
mal motor and sensory function, may have reﬂex abnormalities
Table 2
ASIA impairment scale[7].
ASIA impairment scale Lesion
A No sensory or motor function is preserved in the sacral segments S4–S5 Complete
B Sensory but no motor function is preserved below the neurological level, including the sacral segments S4–S5 Incomplete
C Motor function is preserved below the neurological level, and more than half of key muscles below the neurological
level have a muscle grade less than 3
Incomplete
D Motor function is preserved below the neurological level, and at least half of key muscles below the neurological
level have a muscle grade of 3 or more
Incomplete
E Motor and sensory functions are normal Normal
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systemic), although most scholars do inject those intrathecally,
why not directly over the spinal level of lesion especially
when it has a traumatic nature. But other dilemmas remain as
well, such as those related to the frequency of administration,
the dosage of stem cells to be injected, and last but not least,
the ﬁnal outcome or the overall success of a sophisticated
technique[20]. On the other hand, some studies reporting
successful treatment and optimistic outcomes have beenTable 3
Hauser ambulation index[24].
Index Characteristics
0 Asymptomatic; fully active
1 Walks normally, but reports fatigue that interferes with athletic or other demanding activities
2 Abnormal gait or episodic imbalance; gait disorder is noticed by family and friends; able to walk 25 feet (8 m) in 10 s or less
3 Walks independently; able to walk 25 feet in 20 s or less
4 Requires unilateral support (cane or single crutch) to walk; walks 25 feet in 20 s or less
5 Requires bilateral support (canes, crutches, or walker) and walks 25 feet in 20 s or less; or requires unilateral support but
needs more than 20 s to walk 25 feet
6 Requires bilateral support and more than 20 s to walk 25 feet; may use wheelchair on occasion
7 Walking limited to several steps with bilateral support; unable to walk 25 feet; may use wheelchair for most activities
8 Restricted to wheelchair; able to transfer self independently
9 Restricted to wheelchair; unable to transfer self independentlyperformed on rats, hence the efﬁcacy on humans cannot be
taken for granted[20–22].
Before considering alternative sources of stem cells, direct
transplantations of human neurons have been tried, mainly
through the usage of clonal forms such as human neuro-
teratocarcinoma neurons derived from the human neuro-
teratocarcinoma[21]. Bone marrow stromal cells have been
successfully transplanted in traumatic central spinal cord
cavities of adult rats with chronic paraplegia[22].
Back to humans, the results of an open-label study conducted
on 297 patients regarding the efﬁcacy of autologous human bone
marrow derived mononuclear cell transplantation in SCI have
been reported[23]. It seems that over the last decade, the research
has been focused on the following sources of stem cells: a.
autologous human bone marrow derived mononuclear cells,
with the bone marrow aspirated from the anterior iliac crest
and isolation of the mononuclear fraction by density gradient
method[17,19]; b. co-infusion of autologous adipose tissue
derived mesenchymal stem cell differentiated neuronal cells and
hematopoietic stem cells[18]. For this purpose, adipose tissue was
resected from patients' anterior abdominal wall.
ASIA score has been the standard methodology for reporting
results and outcome of the studies. Some authors have also re-
ported those results strictly related with the ambulation ability ofthe patients through the Hauser index[18,24]. Hauser ambulation
index will obviously ponder the ability/disability and the
severity of the latter with regard to motor activity of the lower
extremities, without evaluating any left sensorial capacity.
However, the ambulation index through focusing on the
remaining motor activities, if any, will reﬂect fairly well the
functionality of the spinal cord below the level of the injury,
although the index itself was not originally conceived for SCI
evaluation (Table 3).Of course, sensation repair in SCI patients under therapy
must be also tested, evaluated and methodologically scored as
well as other vital functions that are not related to ambulation,
but extremely important, such as the bladder control[25].
The actual trend of stem cell sourcing purposefully used to
treat SCI and paraplegia among human patients seems to
conﬁrm that these techniques might yield better and more
reproducible results. However, the use of genuine neural pre-
cursors, such as human neuroteratocarcinoma or olfactory
ensheathing cells, previously tried in pioneering studies in rats
and actually even in humans, is of interest[26,27].
The predilection of different methodologies in producing
stem cells might be related with technical issues, such as the ease
of obtaining bone marrow material aspirated from the iliac crest
or adipose tissue from the abdominal wall (generating neuronal
stem cells from autologous tissue derived mesenchymal pre-
cursors). But a diversity of factors will inﬂuence the overall
success of a transplantation attempt.
4. Conclusive remarks
With the wide acceptance of efﬁcacy of glucocorticoids during
the acute phase of SCI, and following grounded and numerous
reports of stem cell transplantation success in the chronic phase of
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yet clear-cut are extensively outlined. Optimistic approaches to-
ward stem cell therapy have even pushed scholars to advise
repeated transplantation efforts[25]. The timeliness of such
transplantations has been discussed as well. In general, efforts
should be started one year following the initial injury, when the
expectances for a natural recovery become almost zero.
Meanwhile, other aspects of treatment and support of para-
plegia patients need to be considered and taken care of. Being
severely handicapped will not necessarily mean a complete loss
of the sense of life. Surprisingly enough, in what is called the
“disability paradox”, persons with severe impairments tend to
have high quality of life[28]. Such a potential must be fully
exploited, even for psychotherapeutic means.
In a thorough review, Mukand et al.[29] considered the organ
and systemic long-term complications of SCI. Table 4 summa-
rizes those ﬁndings and caveats.Table 4
Systemic SCI complications[29].
Position Complications
Pulmonary Breathing and coughing impairment; atelectasis
and aspiration pneumonia; impaired clearing of
secretions; complications of prolonged intubation
(tracheal stenosis)
Cardiovascular Thromboembolism; deep venous thrombosis;
neurogenic orthostatic hypotension; silent
myocardial ischemia; autonomic dysreﬂexia
Genitourinary Renal failure; urinary incontinence predisposing
to decubitus ulcers; complications of indwelling
catheters (calculi, ﬁstulas); bladder dysfunction
Gastrointestinal Constipation; ileus; fecal impaction; gastric ulcer;
gastro-esophageal reﬂux; nausea; incontinence
Integumentary Decubitus ulcers
Metabolic Heterotopic ossiﬁcationThe list of SCI complications cannot be exhaustive. How-
ever, it is clear that a prompt detection of the occurrences
described in Table 4 will be helpful for an adequate and effective
treatment of those.
Rehabilitation procedures should be put in place as soon as
the general status of the patient allows that, and individually
planned and implemented. Pain is a frequent and sometimes
neglected problem, especially in its neuropathic form. Recently,
some guidelines have been approved in order to standardize its
handling[30]. Orthopedic interventions, even corrective or
palliative, must be considered. Different kinds of jackets,
orthosis, splints, casts and immobilization devices are
available, apart from surgical options[31,32]. With the high
frequency of SCIs following traumatic events, it is not even
surprising that some authors are testing protective devices ad
hoc for protecting the nervous structures[33]. Once considered
as a curse, the prognosis of SCI and paraplegia is expected to
change substantially, with more research focused on stem cell
transplantation options, and with the up-to-date optimistic re-
ports from different sources treating this medical condition.
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